BSH 2017 | Future treatment options for multiple myeloma

Karthik Ramasamy

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD from the Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses future treatment options for multiple myeloma at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Immunomodulatory drugs are commonly used in the treatment of multiple myeloma. The next step is combining different treatments, such as chemotherapy, steroids, and monoclonal antibodies, to achieve deeper remissions and therefore better outcomes for patients.

Share this video